Citadel Advisors’s Axsome Therapeutics AXSM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $47.6M | Buy |
281,503
+143,290
| +104% | +$24.8M | 0.01% | 1412 |
|
|
2025
Q4 | $25.2M | Sell |
138,213
-20,193
| -13% | -$2.82M | ﹤0.01% | 2105 |
|
|
2025
Q3 | $19.2M | Buy |
158,406
+144,788
| +1,063% | +$16.3M | ﹤0.01% | 2392 |
|
|
2025
Q2 | $1.42M | Sell |
13,618
-70,168
| -84% | -$7.43M | ﹤0.01% | 6366 |
|
|
2025
Q1 | $9.77M | Sell |
83,786
-411,603
| -83% | -$46.9M | ﹤0.01% | 2876 |
|
|
2024
Q4 | $41.9M | Buy |
495,389
+190,707
| +63% | +$17.5M | 0.01% | 1438 |
|
|
2024
Q3 | $27.4M | Sell |
304,682
-448,555
| -60% | -$39.2M | 0.01% | 1753 |
|
|
2024
Q2 | $60.6M | Sell |
753,237
-390,407
| -34% | -$28.9M | 0.01% | 1002 |
|
|
2024
Q1 | $91.3M | Buy |
1,143,644
+54,559
| +5% | +$4.58M | 0.02% | 757 |
|
|
2023
Q4 | $86.7M | Sell |
1,089,085
-206,539
| -16% | -$13.8M | 0.02% | 777 |
|
|
2023
Q3 | $90.6M | Buy |
1,295,624
+841,306
| +185% | +$62.9M | 0.02% | 686 |
|
|
2023
Q2 | $32.6M | Buy |
454,318
+255,297
| +128% | +$18.8M | 0.01% | 1402 |
|
|
2023
Q1 | $12.3M | Sell |
199,021
-164,720
| -45% | -$10.8M | ﹤0.01% | 2536 |
|
|
2022
Q4 | $28.1M | Sell |
363,741
-167,596
| -32% | -$10M | 0.01% | 1611 |
|
|
2022
Q3 | $23.7M | Buy |
531,337
+80,342
| +18% | +$4.01M | 0.01% | 1713 |
|
|
2022
Q2 | $17.3M | Buy |
450,995
+213,982
| +90% | +$6.77M | ﹤0.01% | 2007 |
|
|
2022
Q1 | $9.81M | Sell |
237,013
-71,278
| -23% | -$2.21M | ﹤0.01% | 2994 |
|
|
2021
Q4 | $11.6M | Buy |
308,291
+224
| +0.1% | +$8.24K | ﹤0.01% | 2805 |
|
|
2021
Q3 | $10.2M | Sell |
308,067
-261,738
| -46% | -$10.2M | ﹤0.01% | 3048 |
|
|
2021
Q2 | $38.4M | Buy |
569,805
+160,511
| +39% | +$9.63M | 0.01% | 1350 |
|
|
2021
Q1 | $23.2M | Sell |
409,294
-314,845
| -43% | -$22.1M | 0.01% | 1777 |
|
|
2020
Q4 | $59M | Buy |
724,139
+492,133
| +212% | +$36.8M | 0.02% | 836 |
|
|
2020
Q3 | $16.5M | Sell |
232,006
-225,068
| -49% | -$17.5M | ﹤0.01% | 1742 |
|
|
2020
Q2 | $37.6M | Sell |
457,074
-306,420
| -40% | -$23.6M | 0.01% | 989 |
|
|
2020
Q1 | $44.9M | Buy |
763,494
+185,851
| +32% | +$15.1M | 0.02% | 691 |
|
|
2019
Q4 | $59.7M | Buy |
577,643
+453,636
| +366% | +$18.3M | 0.03% | 672 |
|
|
2019
Q3 | $2.51M | Buy |
124,007
+82,473
| +199% | +$2.12M | ﹤0.01% | 4124 |
|
|
2019
Q2 | $1.07M | Buy |
41,534
+8,258
| +25% | +$166K | ﹤0.01% | 5588 |
|
|
2019
Q1 | $474K | Buy |
+33,276
| New | +$309K | ﹤0.01% | 6877 |
|
|
2018
Q3 | – | Sell |
-15,581
| Closed | -$50K | – | 9188 |
|
|
2018
Q2 | $50K | Buy |
+15,581
| New | +$48.3K | ﹤0.01% | 8442 |
|
|
2016
Q4 | – | Sell |
-13,171
| Closed | -$104K | – | 7240 |
|
|
2016
Q3 | $104K | Buy |
+13,171
| New | +$99.7K | ﹤0.01% | 6639 |
|
Other funds holding AXSM
VPM
VCM
DTC
Citadel Advisors's AXSM Position: Q1 2026 in Review
Citadel Advisors increased its Axsome Therapeutics (AXSM) stake by 104% in Q1 2026, buying an estimated $24.8M and bringing the position to 281,503 shares worth $47.6M. The position accounts for 0.01% of the portfolio, ranked #1412.
Citadel Advisors first reported a position in AXSM in Q3 2016 and has held it in 31 quarters since. The position peaked at $91.3M in Q1 2024. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.
- Citadel Advisors held 281,503 shares of Axsome Therapeutics worth $47.6M as of Q1 2026.
- Citadel Advisors bought 143,290 Axsome Therapeutics shares in Q1 2026, an estimated $24.8M.
- Axsome Therapeutics made up 0.01% of Citadel Advisors's portfolio in Q1 2026, its #1412 holding.
- Citadel Advisors first reported a position in Axsome Therapeutics in Q3 2016 and has held it in 31 quarters since.
- Citadel Advisors's Axsome Therapeutics position peaked at $91.3M in Q1 2024.
- 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.